LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the Walter Reed Army Institute of Research (WRAIR). The CRADA will allow the WRAIR to conduct preclinical testing on a novel compound derived from Concert’s DCE Platform™ (deuterated chemical entity platform) for seizure protection associated with traumatic brain injury (TBI), a major public health concern. This CRADA will further advance Concert’s research program for drug compounds that have demonstrated anti-seizure activity in preclinical models and may be effective in the treatment of various epileptic or seizure-generating diseases and injuries, such as ischemic stroke and traumatic brain injury.
